Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 101 publications
Safety and Effectiveness of Nonsteroidal Tapinarof Cream 1% Added to Ongoing Biologic Therapy for Treatment of Moderate to Severe Plaque Psoriasis.
Journal: Cutis
Published: March 16, 2026
Real-world Tildrakizumab Effectiveness and Drug Survival: A Cohort Study in the PPD CorEvitas Psoriasis Registry.
Journal: Dermatology and therapy
Published: February 06, 2026
Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks.
Journal: Dermatology and therapy
Published: February 03, 2026
Treatment Patterns, Drug Survival, and Effectiveness of Tildrakizumab Among Patients with Prior Interleukin-17 Experience in the PPD CorEvitas Psoriasis Registry.
Journal: Dermatology and therapy
Published: January 03, 2026
Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2.
Journal: Dermatology and therapy
Published: December 31, 2025
The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trial.
Journal: Journal of the American Academy of Dermatology
Published: November 20, 2025
Comparative Efficacy of Deucravacitinib and Adalimumab for Scalp Psoriasis: An Indirect Treatment Comparison.
Journal: Journal of drugs in dermatology : JDD
Published: August 07, 2025
Deucravacitinib With Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis.
Journal: Journal of drugs in dermatology : JDD
Published: August 07, 2025
Efficacy and Safety of Risankizumab in Genital or Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16.
Journal: Dermatology and therapy
Published: July 25, 2025
Dupilumab treatment restores skin nerve fibre density in patients with moderate-to-severe atopic dermatitis: results from DIFFERENSTAD, an open-label exploratory study.
Journal: The British journal of dermatology
Published: July 21, 2025
Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study.
Journal: Dermatology and therapy
Published: June 20, 2025
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis over 5 years in patients living with obesity.
Journal: The British journal of dermatology
Published: May 22, 2025
Last Updated: 09/26/2026